rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Nuvation Bio Inc.

NUVB · NYSE

Health CareBiotechnologyNot moving yet

NUVB stood above a rising 150-day average in 23 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 18.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$237K
Insider sales, 12 months
$13.1M
Officials’ trades on record
0
Institutions holding
230 (+10)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$4.3M$0$902KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months16
Buyers · sellers1 · 6
WhoDidSharesTraded
Gary HattersleyCHIEF SCIENTIFIC OFFICERsold100,000at $7.0919 Aug 2026filed 21 Aug 2026
Kerry WentworthCHIEF REGULATORY OFFICERsold63,000at $6.0223 Jun 2026filed 24 Jun 2026
Stacy MarkelCHIEF PEOPLE OFFICERsold125,000at $6.0323 Jun 2026filed 24 Jun 2026
Philippe SauvageChief Financial Officersold47,668at $6.0123 Jun 2026filed 24 Jun 2026
Robert MashalDirectorbought25,000at $4.739 Jun 2026filed 11 Jun 2026
Kerry WentworthCHIEF REGULATORY OFFICERsold36,750at $5.0117 Apr 2026filed 21 Apr 2026
Dongfang LiuCHIEF MEDICAL OFFICERsold50,000at $5.0217 Apr 2026filed 21 Apr 2026
Kerry WentworthCHIEF REGULATORY OFFICERsold200,000at $4.526 Apr 2026filed 8 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders230+10 on the quarter
New · exited38 · 28
Reported value$1.3B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 202652,230,295$296.7M+240,702+0.5%
BlackRock, Inc.added · filed 7 Aug 202627,630,837$156.9M+2,530,463+10.1%
Decheng Capital LLCunchanged · filed 14 Aug 202625,954,439$147.4M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202611,919,514$67.7M+293,316+2.5%
Omega Fund Management, LLCunchanged · filed 14 Aug 20268,081,089$45.9M00.0%
Laurion Capital Management LPreduced · filed 13 Aug 20267,820,013$44.4M-2,6250.0%
STATE STREET CORPadded · filed 7 Aug 20267,370,794$41.9M+585,867+8.6%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20266,244,805$35.5M+381,151+6.5%
AMERICAN CENTURY COMPANIES INCadded · filed 12 Aug 20264,499,643$25.6M+1,602,565+55.3%
BANK OF AMERICA CORPadded · filed 14 Aug 20263,529,748$20.0M+309,922+9.6%
31 Mar 2023 – 30 Jun 2026
104165225Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Gary Hattersley Company insiderCHIEF SCIENTIFIC OFFICER · last 19 Aug 20260 · 3
Philippe Sauvage Company insiderChief Financial Officer · last 15 Jul 20262 · 1
Kerry Wentworth Company insiderCHIEF REGULATORY OFFICER · last 23 Jun 20261 · 3
Stacy Markel Company insiderCHIEF PEOPLE OFFICER · last 23 Jun 20261 · 1
Robert Mashal Company insiderDirector · last 9 Jun 20263 · 0
Kathryn E. Falberg Company insiderDirector · last 21 May 20264 · 0
Kim D. Blickenstaff Company insiderDirector · last 21 May 20261 · 0
Robert B. Bazemore Company insiderDirector · last 21 May 20261 · 0
W. Anthony Vernon Company insiderDirector · last 21 May 20260 · 0
Xiangmin Cui Company insiderDirector · last 21 May 20264 · 0
Dongfang Liu Company insiderCHIEF MEDICAL OFFICER · last 17 Apr 20260 · 8
Colleen Sjogren Company insiderChief Commercial Officer · last 27 Feb 20261 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2024 · to 31 Dec 202410.1%
Operating profit marginFY 2025 · to 31 Dec 2025-339%
Return on capital employedFY 2025 · to 31 Dec 2025-41.6%
Debt to equityFY 2025 · to 31 Dec 20250.17×
Interest coverFY 2025 · to 31 Dec 2025-21.02×
Research spendFY 2025 · to 31 Dec 2025183%
Cash and equivalentsFY 2025 · to 31 Dec 2025$164.1M

Analyst forecasts

No analyst forecasts yet.